Table 3.
Comparison of ETV, TDF, and TAF on reduction of HCC
| Study area | Patients | Outcome | Superiority or equality | Reference | Year |
|---|---|---|---|---|---|
| Korea | |||||
|
| |||||
| National Cohort | ETV: 11,464, TDF: 12,692' | ETV: 1.19/100 PY, TDF: 0.89/100 PY | TDF > ETV | Choi etal. [24] | 2019 |
|
| |||||
| Hospital Cohort | ETV: 1,560, TDF: 1,141 | HR 0.68, 95% CI: 0.60–0.78, HR 0.68, 95% CI: 0.46–0.99 | |||
|
| |||||
| Korea | ETV: 1,484, TDF: 1,413 | ETV: 1.92/100 PY, TDF: 1.69/100 PY, HR 0.975, p = 0.852 | ETV = TDF | Kim etal. [16] | 2019 |
|
| |||||
| Korea | ETV: 1,583, TDF: 1,439 | HR 1.030,95% CI: 0.703–1.509 p = 0.880 | TDF = ETV | Lee et al. [15] | 2020 |
|
| |||||
| Korea | ETV: 180, TDF: 224 | HR 0.36, 95% CI: 0.12–1.14 p = 0.08 | ETV = TDF | Ha etal. [61] | 2020 |
|
| |||||
| Korea | ETV: 813, TDF: 882 | HR 0.82, 95% CI: 0.68–0.98 p = 0.03 (after surgical resection) | TDF > ETV | Choi etal. [10] | 2021 |
|
| |||||
| Korea | ETV: 1,525, TAF: 286 | ETV: 1.67/100 PY, TAF: 1.19/100 PY, HR 0.681,95% CI: 0.351–1.320, p = 0.255 | ETV=TAF | Lee etal. [48] | 2021 |
|
| |||||
| Korea | TDF: 2,245, TAF: 502 | TDF: 0.90/100PY, TAF: 0.82/100PY, p = 0.60 | TDF = TAF | Lim et al. [49] | 2022 |
|
| |||||
| China | ETV: 2,124, TDF: 1,574 | RR 0.66,95% CI: 0.49–0.89, p = 0.008 | TDF > ETV | Zhang etal. [12] | 2019 |
|
| |||||
| China | ETV: 28,041, TDF: 1,309 | ETV: 0.49/100 PY, TDF: 0.06/100 PY, HR 0.36,95% CI: 0.16–0.80, p = 0.013 | TDF > ETV | Yip etal. [11] | 2020 |
|
| |||||
| Taiwan and Asia-Pacific | ETV: 4,837, TDF: 700 | HR 0.89; 95% CI: 0.41–1.92, p = 0.77 | TDF = ETV | Hsu etal. [14] | 2020 |
|
| |||||
| Taiwan and Asia-Pacific | ETV: 19,702, TDF: 16,266 | ETV: 3.44%/5Y, TDF: 3.39%/5Y, HR 0.88, 95% CI: 0.73–1.07 p = 0.20 | TDF = ETV | Tseng et al. [71] | 2020 |
|
| |||||
| Hong Kong and China | ETV: 56,346, TDF: 28,662 | HR 0.73, 95% CI: 0.62–0.85 p < 0.001 | TDF > ETV | Cheung etal. [70] | 2020 |
|
| |||||
| Europe | ETV: 772, TDF: 1,163 | ETV: 1.08/100 PY, TDF: 1.2/100 PY, p = 0.321 | ETV = TDF | Papatheodoridis et al. [72] | 2020 |
|
| |||||
| USA | ETV: 2,193, TDF: 1,094 | HR 1.00, 95% CI: 0.76–1.32 | ETV = TDF | Su etal. [73] | 2021 |
ETV, entecavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide fumarate; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; PY, person-years; RR, rate ratio – HR combined with incidence rate ratios; Y, year.